Transmembrane Transporters High Sales, High Potential as Drug Targets

The transporter-targeted drug market is forecast to reach $153.8 billion in 2010 and more than 100 transporter drug targets are under commercial investigation.

Transporters represent a highly druggable class of targets and are addressed by many successful drugs on the market. Of the 957 or so human transporter genes, around 10 percent are being targeted for therapeutic effects, which leaves a large number of potential targets unexplored. As additional transporters are characterized and their structures are elucidated competition in this field is likely to increase.

Report Overview

D&MD's Transmembrane Transporters: High Sales, High Potential as Drug Targets maket report comprehensively reviews transmembrane transporters (including ion channels) and assesses their importance as drug targets. Data presented in this report demonstrates that among the top 100 best-selling drugs in the US in 2004, transporters represent the most abundant class of targets. This report will guide readers assessing or reassessing their strategies with respect to this target class.

An on-line survey conducted specially for this report shows that transporters (alongside protein kinases), are regarded as commercially the most promising targets available to the drug industry. Although much has been learned about transporters as drug targets, it is only very recently that scientists have been able to directly examine three-dimensional ion channel and other integral membrane transporter structures.

As the number of published transporter structures multiply, the opportunities to develop more specific transporter-targeting drugs will increase. Companies need to prepare themselves to exploit these opportunities.

In reviewing individual transporter targets in this report we have adopted a gene family-based approach, whereby each transporter is discussed within the context of the family to which it belongs. A comprehensive survey of the Pharmaprojects database provided information on drugs targeting over 100 transporters. This information is utilized in the discussion of transporter members of individual families, thus allowing transporter families to be analyzed from a commercial perspective.

Key Reasons to Purchase

Analyzes the 100 best-selling drugs on the US market to help the reader to appreciate the importance of transporter targets

Presents the results of a survey of 1,302 transporter drugs and their targets to give the reader an appreciation of the transporter drug landscape

Estimates current market sizes and makes forecasts to 2010 to assist the reader with formulating business plans in the transporter drug area

Analyzes leading indications for transporter drugs and highlights areas of unmet need to enable the reader to formulate a strategy for business development

Questions Answered

Which transporter targets are being pursued by drug developers?

What is the nature of commercial activity surrounding each transporter target?

Which transporter targets have attracted the greatest amount of interest from drug developers?

What are the most popular therapeutic indications for transporter drugs?

What are the areas of unmet need that new transporter drugs could address?

What are the most promising applications for transporters outside drug discovery?

Which companies are the most prolific developers of transporter drugs and what drugs are in their portfolios?

By Drs Sreten Bogdanovic and Beata Langlands

Published: June, 2006 Format: PDF or Printed Pages 308
Table of Contents
Detailed Table of Contents and Executive Summary

Price